CureVac NV
CVAC5.280USD
+0.050+0.96%
Fechamento 11/11, 16:00（ET）Cotações atrasadas em 15 min
1.19BValor de mercado
6.14P/L TTM
Mais detalhes de CureVac NV Empresa
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Informações de CureVac NV
Código da empresaCVAC
Nome da EmpresaCureVac NV
Data de listagemAug 14, 2020
CEODr. Alexander Zehnder, M.D.
Número de funcionários825
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 14
EndereçoFriedrich-Miescher-Str. 15
CidadeTUEBINGEN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísGermany
Código postal72076
Telefone49707198830
Sitehttps://www.curevac.com/
Código da empresaCVAC
Data de listagemAug 14, 2020
CEODr. Alexander Zehnder, M.D.
Executivos da empresa CureVac NV
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Malte Greune, Ph.D.
Dr. Malte Greune, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
--
--
Dr. Debra Barker, M.D.
Dr. Debra Barker, M.D.
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Dr. Alexander Zehnder, M.D.
Dr. Alexander Zehnder, M.D.
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Myriam Mendila, M.D.
Dr. Myriam Mendila, M.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Baron Jean Stephenne
Mr. Baron Jean Stephenne
Independent Chairman of Supervisory Board
Independent Chairman of Supervisory Board
40.49K
+141.65%
Dr. Mathias Hothum, Ph.D.
Dr. Mathias Hothum, Ph.D.
Member of the Supervisory Board
Member of the Supervisory Board
29.31K
+170.24%
Mr. Craig A. Tooman
Mr. Craig A. Tooman
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
27.79K
+187.92%
Mr. Michael Brosnan
Mr. Michael Brosnan
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
19.75K
+371.79%
Mr. Axel-Sven Malkomes
Mr. Axel-Sven Malkomes
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Klaus Schollmeier, Ph.D.
Dr. Klaus Schollmeier, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
Switzerland
1.06M
85.06%
Belgium (Country)
186.00K
14.94%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: seg, 10 de nov
Atualizado em: seg, 10 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
Outro
42.80%
Investidores
Investidores
Proporção
DH Capital GmbH & Co. KG
31.17%
KfW
13.27%
Glaxo Group, Ltd.
7.37%
DH-LT-Investments GmbH
3.89%
Zweite DH Verwaltungs GmbH
1.51%
Outro
42.80%
Tipos de investidores
Investidores
Proporção
Corporation
36.61%
Government Agency
13.27%
Holding Company
7.37%
Hedge Fund
2.12%
Investment Advisor/Hedge Fund
1.85%
Investment Advisor
1.18%
Foundation
0.70%
Research Firm
0.69%
Bank and Trust
0.25%
Outro
35.96%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
245
15.20M
6.75%
-13.07M
2025Q2
250
140.06M
62.20%
-14.31M
2025Q1
256
140.77M
62.52%
-15.67M
2024Q4
257
142.22M
63.40%
-15.15M
2024Q3
264
144.04M
64.21%
-15.50M
2024Q2
284
147.06M
65.56%
-13.88M
2024Q1
303
150.44M
67.06%
-10.89M
2023Q4
317
154.94M
69.64%
-16.33M
2023Q3
339
166.99M
75.03%
-5.02M
2023Q2
359
168.77M
75.83%
-4.22M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
DH Capital GmbH & Co. KG
70.18M
31.17%
--
--
Jun 12, 2025
KfW
29.87M
13.27%
--
--
Aug 01, 2025
Glaxo Group, Ltd.
16.59M
7.37%
--
--
Aug 07, 2025
DH-LT-Investments GmbH
8.75M
3.89%
--
--
Jun 12, 2025
Zweite DH Verwaltungs GmbH
3.40M
1.51%
--
--
Jun 12, 2025
Alpine Associates Management Inc.
1.97M
0.88%
+1.97M
--
Jun 30, 2025
Bill & Melinda Gates Foundation
1.57M
0.7%
-28.77K
-1.80%
Sep 30, 2024
Qube Research & Technologies Ltd
1.18M
0.53%
+1.18M
--
Jun 30, 2025
Water Island Capital, LLC
957.03K
0.42%
+957.03K
--
Jun 30, 2025
Glazer Capital, LLC
594.85K
0.26%
+594.85K
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
AltShares Merger Arbitrage ETF
1.3%
Virtus LifeSci Biotech Clinical Trials ETF
0.69%
Global X Genomics & Biotechnology ETF
0.59%
NYLI Merger Arbitrage ETF
0.57%
WisdomTree BioRevolution Fund
0.5%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.12%
SPDR S&P International Small Cap ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI Europe Small-Cap ETF
0.04%
Ver Mais
AltShares Merger Arbitrage ETF
Proporção1.3%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.69%
Global X Genomics & Biotechnology ETF
Proporção0.59%
NYLI Merger Arbitrage ETF
Proporção0.57%
WisdomTree BioRevolution Fund
Proporção0.5%
ProShares Ultra Nasdaq Biotechnology
Proporção0.13%
Invesco Nasdaq Biotechnology ETF
Proporção0.12%
SPDR S&P International Small Cap ETF
Proporção0.05%
iShares Biotechnology ETF
Proporção0.05%
iShares MSCI Europe Small-Cap ETF
Proporção0.04%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
